193 related articles for article (PubMed ID: 37815625)
21. Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studie.
Govoni M; Batalov A; Boumpas DT; D'Angelo S; De Keyser F; Flipo RM; Kellner H; Leroi H; Khalifa A
Clin Exp Rheumatol; 2024 Mar; 42(3):642-650. PubMed ID: 37976120
[TBL] [Abstract][Full Text] [Related]
22. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
23. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database.
Scirè CA; Caporali R; Sarzi-Puttini P; Frediani B; Di Franco M; Tincani A; Sinigaglia L; Sfriso P; Tirri R; Bellis E; Delsante G; Porru G; Salaffi F; Giuggioli D; Rossini M; Todoerti M; Bazzichi L; Govoni M; Gerli R; Raschetti R; Minisola G; Montecucco C; Todesco S;
Clin Exp Rheumatol; 2013; 31(6):857-63. PubMed ID: 23981363
[TBL] [Abstract][Full Text] [Related]
24. Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial.
Song IH; Hermann KG; Haibel H; Althoff CE; Poddubnyy D; Listing J; Weiß A; Buß B; Freundlich B; Lange E; Alten R; Rudwaleit M; Sieper J
J Rheumatol; 2014 Oct; 41(10):2034-40. PubMed ID: 25028375
[TBL] [Abstract][Full Text] [Related]
25. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
26. Effect of Secukinumab and Tumor Necrosis Factor Inhibitors on Humoral Response to BNT162b2 mRNA Vaccine in Patients With Spondyloarthritis Compared to Immunocompetent Controls.
Eviatar T; Furer V; Polachek A; Zisman D; Peleg H; Elalouf O; Levartovsky D; Kaufman I; Broyde A; Haddad A; Feld J; Aassi M; Quebe-Fehling E; Alarcon I; Pel S; Paran D; Elkayam O
J Rheumatol; 2024 Apr; 51(4):415-422. PubMed ID: 37914221
[TBL] [Abstract][Full Text] [Related]
27. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
Pombo-Suárez M; Seoane-Mato D; Díaz-González F; Cea-Calvo L; Sánchez-Alonso F; Sánchez-Jareño M; Jovani V; García-Magallón B; Martínez-González O; Campos-Fernández C; Manero J; Díaz-Torne C; Bohórquez C; Ros-Vilamajó I; Pérez-Vera Y; Castrejón I
Musculoskeletal Care; 2023 Mar; 21(1):189-197. PubMed ID: 35996810
[TBL] [Abstract][Full Text] [Related]
28. Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Iannone F; Santo L; Anelli MG; Bucci R; Semeraro A; Quarta L; D'Onofrio F; Marsico A; Carlino G; Casilli O; Cacciapaglia F; Zuccaro C; Falappone PC; Cantatore FP; Muratore M; Lapadula G
Semin Arthritis Rheum; 2017 Aug; 47(1):108-114. PubMed ID: 28216195
[TBL] [Abstract][Full Text] [Related]
29. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
[TBL] [Abstract][Full Text] [Related]
30. Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis.
Michelsen B; Ørnbjerg LM; Kvien TK; Pavelka K; Nissen MJ; Nordström D; Santos MJ; Koca SS; Askling J; Rotar Z; Gudbjornsson B; Codreanu C; Loft AG; Kristianslund EK; Mann HF; Ciurea A; Eklund KK; Vieira-Sousa E; Yazici A; Jacobsson L; Tomšič M; Löve TJ; Ionescu R; van der Horst-Bruinsma IE; Iannone F; Pombo-Suarez M; Jones GT; Hyldstrup LH; Krogh NS; Hetland ML; Østergaard M
Rheumatology (Oxford); 2020 Sep; 59(9):2455-2461. PubMed ID: 31960053
[TBL] [Abstract][Full Text] [Related]
31. Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort.
Yahya F; Gaffney K; Hamilton L; Lonsdale E; Leeder J; Brooksby A; Cavill C; Berry-Jenkins J; Boyle C; Bond D; Sengupta R;
Rheumatology (Oxford); 2018 Apr; 57(4):619-624. PubMed ID: 29272541
[TBL] [Abstract][Full Text] [Related]
32. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.
Ørnbjerg LM; Linde L; Georgiadis S; Rasmussen SH; Lindström U; Askling J; Michelsen B; Giuseppe DD; Wallman JK; Pavelka K; Závada J; Nissen MJ; Jones GT; Relas H; Pirilä L; Tomšič M; Rotar Z; Geirsson AJ; Gudbjornsson B; Kristianslund EK; van Sder Horst-Bruinsma I; Loft AG; Laas K; Iannone F; Corrado A; Ciurea A; Santos MJ; Santos H; Codreanu C; Akkoc N; Gunduz OS; Glintborg B; Østergaard M; Hetland ML
Semin Arthritis Rheum; 2022 Oct; 56():152081. PubMed ID: 35985172
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort.
Pina Vegas L; Sbidian E; Wendling D; Goupille P; Ferkal S; Le Corvoisier P; Ghaleh B; Luciani A; Claudepierre P
Rheumatology (Oxford); 2022 Apr; 61(4):1487-1495. PubMed ID: 34270707
[TBL] [Abstract][Full Text] [Related]
34. The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis.
Lubrano E; Perrotta FM; Manara M; D'Angelo S; Addimanda O; Ramonda R; Punzi L; Olivieri I; Salvarani C; Marchesoni A
J Rheumatol; 2018 Feb; 45(2):195-201. PubMed ID: 29419448
[TBL] [Abstract][Full Text] [Related]
35. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases.
Pombo-Suárez M; Seoane-Mato D; Díaz-González F; Sánchez-Alonso F; Sánchez-Jareño M; Cea-Calvo L; Castrejón I
Adv Rheumatol; 2023 Jun; 63(1):25. PubMed ID: 37287051
[TBL] [Abstract][Full Text] [Related]
36. Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it.
Padilla-Martínez EM; Romero-Sanchez C; Bello-Gualtero JM; Mesa-Betancourt AM; Bautista-Molano W; Valle-O R
Curr Rheumatol Rev; 2019; 15(4):329-335. PubMed ID: 31284866
[TBL] [Abstract][Full Text] [Related]
37. Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study.
Nakayama Y; Watanabe R; Murakami K; Murata K; Tanaka M; Ito H; Yamamoto W; Ebina K; Hata K; Hiramatsu Y; Katayama M; Son Y; Amuro H; Akashi K; Onishi A; Hara R; Yamamoto K; Ohmura K; Matsuda S; Morinobu A; Hashimoto M
Rheumatol Int; 2022 Jul; 42(7):1227-1234. PubMed ID: 35266034
[TBL] [Abstract][Full Text] [Related]
38. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
Micheroli R; Hebeisen M; Wildi LM; Exer P; Tamborrini G; Bernhard J; Möller B; Zufferey P; Nissen MJ; Scherer A; Ciurea A;
Arthritis Res Ther; 2017 Jul; 19(1):164. PubMed ID: 28724442
[TBL] [Abstract][Full Text] [Related]
39. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
40. Risk of disease flare in spondyloarthritis patients after tapering tumor necrosis factor inhibitors: A meta-analysis and literature review.
Min HK; Kim HR; Lee SH; Nam B; Shin JH; Kim TH
Int Immunopharmacol; 2024 Jun; 134():112167. PubMed ID: 38754279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]